FDA, Cancer, Multiple Myeloma discussed on Scotty O'Brien


Institute is is always encouraged and leads to. Leads to successes and new new treatments being developed. I think more work needs to be done on the reimbursement side, especially with these new therapies like I've just described. I am not an expert in public policy or government relations for healthcare. But I do know that we were these new gene therapies like Kartini cell therapy. We need to figure out a way to to fund sustainably the treatment of Medicare patients in particular who need these therapies. When we are looking ahead at some of the trials that are going to understand that there are a lot of moving parts. And and you know, you you don't necessarily have a timetable on when things are going to get done. I've been any specific breakthroughs, or at least maybe some positive signs on on any of those particular fronts with regard to treatments that maybe they are at least signs of treatments that are coming that. Maybe he didn't have much hope for maybe six months ago or a year ago absolutely within each of those categories of blood cancers, we've had successes come along. I mentioned cartoons cell therapy. That's been FDA approved within the last year. And that's offer treatment hope for people who really were without hope. In leukemia particular, acute myeloid leukemia. There's been several new FDA approved medications to treat AM L or acute myeloid leukemia within the last several months, and in fact prior there hadn't been FDA approved therapies for refractory and Allen and decades. So we're certainly making progress in the fight against multiple myeloma fifteen twenty years ago, it was a grim prognosis, and we now have a number of different categories of treatments for multiple myeloma patients that have have come along within the last ten years or her a little bit longer. And now we're continuing to refine and survival is improved for all these categories have blood cancer within the last ten years. So there are some positive there's some positive steps in some some noted progress that's being made yet from the. Formation. I understand let your team sent me that I guess less than five percent of adults living with cancer will enroll in a cancer clinical trial. Why is that? Well, not every cancer physician or cancer center will offer clinical trials or they may not offer clinical trials specific to the type of cancer that that patient has. But I think it's truly important that that cancer patients and their families are aware of clinical trials this offer what he's are offering treatments that doctors and scientists believe could be better than what currently exists and all those new treatments that I've mentioned are because people were willing to engage in clinical trials, try new things out. And so I always encourage people to seek out what clinical trials there could be eligible for. And and I think we need to encourage people to get second. Opinions. There's a lot that we've covered here, and certainly the mood. Imagine that part of our audience has a need to find out more for.

Coming up next